Skip to main content

Pilot Test of Vital Signs and Laboratory Results Table Descriptive Modules in the Sentinel Distributed Database

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    sitagliptin
    sodium-glucose cotransporter-2 (SGLT-2) inhibitor
    Health Outcome(s)
    hypertension
    Description

    The proposed goal of this project was to pilot, via two use cases, the ability to more routinely and broadly understand how FDA might conduct “on-demand quality assurance” for selected vital signs and laboratory results in a within cohort fashion. The first use case evaluated a cohort of pediatric patients with hypertension. The second use case evaluated a cohort of new adult users of sodium-glucose co-transporter-2 (SGLT-2) inhibitors.

    Vital signs and laboratory measures were evaluated for each use case. Measures included blood pressure as well as smoking use/status, height, and weight. Laboratory tests included Hemoglobin A1c and creatinine.

    A comparison of the identification using a claims-only phenotype versus a clinical data (e.g., electronic health record based) phenotype was conducted. Two reports are posted from the first use case that evaluated a cohort of pediatric patients with hypertension. In the first report, the hypertension algorithm is simplified. The second report utilized a more complex hypertension algorithm to define events of interest. Two reports are posted from the second use case that evaluated counts of individuals with SGLT-2 inhibitor and sitagliptin dispensings in the Sentinel Distributed Database (SDD) along with baseline conditions and other medication use. The first report did not include integrated delivery systems data in the analysis; the second report only included integrated delivery systems data in the analysis.

    Workgroup Leader(s)

    Judith C. Maro, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

    Danijela Stojanovic, PharmD, PhD; Brian Kit, MD; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

    Workgroup Member(s)

    Jennifer Lyons, PhD; Nicole Haug, MPH; Casie Horgan, MPH; Jillian Burk, MPH; Soowoo Back, MPH; Meredith Cantwell, MScPH; Alex Peters, MPH; Sandra DeLuccia, MPH; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA

    Efe Eworuke, PhD; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD